Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.

about

Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.

Item

http://www.wikidata.org/entity/Q47229461

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Difference in causes and progn ...... acute promyelocytic leukemia.

@en

Difference in causes and progn ...... acute promyelocytic leukemia.

@nl

type

Item

label

Difference in causes and progn ...... acute promyelocytic leukemia.

@en

Difference in causes and progn ...... acute promyelocytic leukemia.

@nl

prefLabel

Difference in causes and progn ...... acute promyelocytic leukemia.

@en

Difference in causes and progn ...... acute promyelocytic leukemia.

@nl

P1476

Difference in causes and progn ...... d acute promyelocytic leukemia

@en

P2093

Bo Jin

http://www.w3.org/2001/XMLSchema#string

Fei Ge

http://www.w3.org/2001/XMLSchema#string

Fenglin Cao

http://www.w3.org/2001/XMLSchema#string

Haitao Li

http://www.w3.org/2001/XMLSchema#string

Hongli Zhao

http://www.w3.org/2001/XMLSchema#string

Huiyuan Yang

http://www.w3.org/2001/XMLSchema#string

Jiayue Sun

http://www.w3.org/2001/XMLSchema#string

Jinxiao Hou

http://www.w3.org/2001/XMLSchema#string

Jinyue Fu

http://www.w3.org/2001/XMLSchema#string

Ping Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.

Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.

The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.

Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.

Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.

International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia.

P304

409-416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3216-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jin Zhou

P577

2017-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29289982

http://www.w3.org/2001/XMLSchema#string